Veracyte
VCYT
58 hedge funds and large institutions have $77.5M invested in Veracyte in 2016 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 21 increasing their positions, 14 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 14
5% more funds holding
Funds holding: 55 → 58 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
6% less capital invested
Capital invested by funds: $82.4M → $77.5M (-$4.91M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $1.24M
Top Buyers
Top Sellers
VCYT Hedge Fund Activity: Q2 2016 in Review
58 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Veracyte (VCYT) for Q2 2016, worth a combined $77.5M — down 6% from $82.4M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new VCYT positions and 4 closed out — a net gain of 3 holders — while 21 added to existing stakes and 14 trimmed.
The largest buyer was Acuta Capital Partners, adding an estimated $2.42M. The largest seller was Clough Capital Partners, cutting an estimated $3.48M.
- 58 institutional investors held Veracyte (VCYT) as of Q2 2016, up from 55 in Q1 2016.
- Funds reported $77.5M of Veracyte stock for Q2 2016, down 6% quarter-over-quarter.
- 7 funds opened new Veracyte positions in Q2 2016 and 4 closed out, a net change of +3 holders.
- The largest Veracyte buyer in Q2 2016 was Acuta Capital Partners, an estimated $2.42M added.
- The largest Veracyte seller in Q2 2016 was Clough Capital Partners, an estimated $3.48M sold.
Based on aggregated 13F filings for Q2 2016.